Michael J. Reed

Q: What Schools Are Affiliated With Michael J. Reed

Michael J. Reed is affiliated with the following schools: University of Bath, Imperial College London, University of Oxford

Michael J. Reed's AcademicInfluence.com Rankings

Michael J. Reed

Biology

#13861

World Rank

#17457

Historical Rank

Molecular Biology

#2544

World Rank

#2585

Historical Rank

Biochemistry

#2551

World Rank

#2718

Historical Rank

biology Degrees

Download Badge

Biology

Michael J. Reed's Degrees

Bachelors Biochemistry University of Oxford

Why Is Michael J. Reed Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Professor Michael J. Reed was a British chemist who held the position of professor of steroid biochemistry at Imperial College, London. Scientific career Reed obtained a BSc in zoology from the University of London in 1967 and an MSc in biochemistry from Imperial College in 1969. He then commenced research into the actions and metabolism of ethinyloestradiol with Ken Fotherby at the Royal Postgraduate Medical School, London, culminating in a PhD in 1973. He continued to work on the regulation of oestrogen synthesis in endometrial cancer before moving to St Mary's Hospital Medical School in 1976, to join Vivian James in the Department of Chemical Pathology. He then focused his attention to the regulation of aromatase in breast cancer.

(See a Problem?)

Michael J. Reed's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. (2000) (725)
Steroid sulfatase: molecular biology, regulation, and inhibition. (2005) (468)
Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor (2006) (223)
Aromatase activity and interleukin-6 production by normal and malignant breast tissues. (1995) (212)
Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. (1994) (205)
Class III β-tubulin expression and in vitro resistance to microtubule targeting agents (2009) (158)
Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. (1995) (156)
Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. (2000) (149)
Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. (1997) (137)
Estrogen synthesis by osteoblast cell lines. (1992) (133)
Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. (1998) (131)
Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. (2008) (130)
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities. (1998) (128)
Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors (1993) (118)
17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer (2008) (118)
Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents (2004) (112)
Steroid sulfatase: a new target for the endocrine therapy of breast cancer. (2007) (101)
Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. (1993) (100)
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. (2006) (98)
In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. (2000) (90)
The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity (1998) (88)
The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. (1999) (80)
Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. (2010) (80)
The effect of 2‐methoxyoestrone‐3‐O‐sulphamate on the growth of breast cancer cells and induced mammary tumours (2000) (79)
E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. (2005) (77)
In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone‐3‐O‐sulphamate (1995) (77)
Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells. (2000) (75)
Dual aromatase-steroid sulfatase inhibitors. (2007) (74)
The Role of 17β-Hydroxysteroid Dehydrogenases in Modulating the Activity of 2-Methoxyestradiol in Breast Cancer Cells (2006) (74)
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents. (2005) (73)
Masoprocol (nordihydroguaiaretic acid): a new antihyperglycemic agent isolated from the creosote bush (Larrea tridentata). (1998) (71)
Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity. (2008) (71)
Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates (2000) (71)
Isolation and antihyperglycemic activity of bakuchiol from Otholobium pubescens (Fabaceae), a Peruvian medicinal plant used for the treatment of diabetes. (1999) (70)
Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism (1996) (69)
Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. (2003) (69)
Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. (1996) (68)
Tibolone: a selective tissue estrogenic activity regulator (STEAR). (2004) (67)
The interaction of cytokines in regulating oestradiol 17β-hydroxysteroid dehydrogenase activity in MCF-7 cells (1994) (67)
Inhibition of in vitro angiogenesis by 2‐methoxy‐ and 2‐ethyl‐estrogen sulfamates (2004) (66)
Steroid sulphatase inhibitors for breast cancer therapy (2003) (64)
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. (2006) (64)
First dual aromatase-steroid sulfatase inhibitors. (2003) (64)
The development of steroid sulphatase inhibitors (1996) (62)
Regulation of steroid sulphatase expression and activity in breast cancer (2000) (61)
In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. (1996) (56)
In vivo Efficacy of STX213, A Second-Generation Steroid Sulfatase Inhibitor, for Hormone-Dependent Breast Cancer Therapy (2006) (55)
Control of aromatase activity in breast tumours: the role of the immune system (1997) (53)
D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. (2003) (53)
Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate (2003) (52)
The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells (1994) (52)
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity. (2007) (50)
STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells (2008) (50)
Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. (2005) (49)
Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. (2007) (49)
Non-steroidal and steroidal sulfamates: new drugs for cancer therapy (2001) (48)
Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity. (2007) (48)
Benzothiazole derivatives as novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (2006) (48)
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. (2008) (47)
Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. (1999) (47)
Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent. (2005) (46)
Novel 18β-glycyrrhetinic acid analogues as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenases (2004) (46)
In‐vivo and in‐vitro models of type 2 diabetes in pharmaceutical drug discovery (1999) (46)
2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer (2008) (46)
Novel antihyperglycemic terpenoid-quinones from Pycnanthus angolensis. (2000) (45)
Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates (2005) (42)
In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol (2007) (42)
Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity (2003) (41)
The Development of Steroid Sulfatase Inhibitors for Hormone‐Dependent Cancer Therapy (2009) (41)
The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. (2008) (41)
Oestrogen uptake and metabolism in vivo (1989) (41)
Exercise adds to metformin and acarbose efficacy in db/db mice. (2001) (41)
The role of cytokines and sulphatase inhibitors in regulating oestrogen synthesis in breast tumours (1995) (40)
Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. (2008) (40)
Human granulosa cells are a site of sulphatase activity and are able to utilize dehydroepiandrosterone sulphate as a precursor for oestradiol production. (2000) (39)
Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase. (2004) (38)
A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor (2008) (38)
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate. (2010) (38)
Focused Libraries of 16‐Substituted Estrone Derivatives and Modified E‐Ring Steroids: Inhibitors of 17ß‐Hydroxysteroid Dehydrogenase Type 1 (2006) (38)
Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography (2008) (37)
Steroid sulphatase inhibitors: A new endocrine therapy (1984) (37)
Inhibition of MDA‐MB‐231 cell cycle progression and cell proliferation by C‐2‐substituted oestradiol mono‐ and bis‐3‐O‐sulphamates (2005) (37)
2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique (2008) (36)
A letrozole-based dual aromatase–sulphatase inhibitor with in vivo activity (2005) (36)
Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. (2003) (36)
Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate (2003) (36)
The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells (2003) (35)
17β-Hydroxysteroid dehydrogenase Type 1 and Type 2: Association between mRNA expression and activity in cell lines (2006) (35)
Oestrogen sulphatase activity in hormone‐dependent and hormone‐independent breast‐cancer cells: Modulation by steroidal and non‐steroidal therapeutic agents (1992) (35)
2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor. (2004) (35)
Regulation and Inhibition of Steroid Sulfatase Activity in Breast Cancer a (1996) (35)
Recent advances in the development of steroid sulphatase inhibitors (1999) (34)
Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer (2008) (33)
The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells (2005) (33)
First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. (2005) (32)
Recent developments of steroid sulfatase inhibitors as anti-cancer agents. (2008) (31)
Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. (2001) (31)
Estrone sulfonates as inhibitors of estrone sulfatase (1997) (31)
2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents. (2004) (30)
Novel non-steroidal inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (2007) (30)
2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases (2004) (29)
The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors (2009) (29)
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. (2006) (28)
Modulation of oestrone sulphatase activity in breast cancer cell lines by growth factors (1992) (28)
Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3-O-sulfamates: synthesis, in vitro evaluation and computational modelling. (2008) (27)
Phosphonates and thiophosphonates as sulfate surrogates: synthesis of estrone 3-methylthiophosphonate, a potent inhibitor of estrone sulfatase (1993) (27)
Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats (2004) (27)
Chimeric microtubule disruptors. (2010) (27)
Novel, potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (2006) (26)
Bicyclic Derivatives of the Potent Dual Aromatase–Steroid Sulfatase Inhibitor 2‐Bromo‐4‐{[(4‐cyanophenyl)(4H‐1,2,4‐triazol‐4‐yl)amino]methyl}phenylsulfamate: Synthesis, SAR, Crystal Structure, and in vitro and in vivo Activities (2010) (26)
Steroid sulphatase: expression, isolation and inhibition for active-site identification studies. (1998) (25)
The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers (2007) (25)
Preferential alteration of inducible gene expression in vivo by carcinogens that induce bulky DNA lesions (1993) (25)
Non‐Steroidal Aromatase Inhibitors Based on a Biphenyl Scaffold: Synthesis, in vitro SAR, and Molecular Modelling (2008) (25)
Measurement of oestrone sulphatase activity in white blood cells to monitor in vivo inhibition of steroid sulphatase activity by oestrone-3-O-sulphamate (1997) (24)
Regulation of aromatase and sulphatase in breast tumour cells. (1996) (24)
Estrone 3-sulfate mimics, inhibitors of estrone sulfatase activity: homology model construction and docking studies. (2002) (23)
Oestrone 3-O-(N-acetyl)sulphamate, a potential molecular probe of the active site of oestrone sulphatase☆ (1997) (23)
Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate (2000) (22)
STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice (2013) (22)
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure (2009) (22)
Synthesis of Aromatase Inhibitors and Dual Aromatase Steroid Sulfatase Inhibitors by Linking an Arylsulfamate Motif to 4‐(4H‐1,2,4‐triazol‐4‐ylamino)benzonitrile: SAR, Crystal Structures, in vitro and in vivo Activities (2008) (22)
Inhibition of human and rat 11β-hydroxysteroid dehydrogenase type 1 by 18β-glycyrrhetinic acid derivatives (2007) (21)
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase Type 3 (2009) (21)
The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. (2004) (21)
The Role of 17 B -Hydroxysteroid Dehydrogenases in Modulating the Activity of 2-Methoxyestradiol in Breast Cancer Cells (2005) (20)
A novel 18β-glycyrrhetinic acid analogue as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 2 (2004) (20)
Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues (2005) (20)
The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-α on endothelial and fibroblast cell growth, morphology and apoptosis (2003) (20)
Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts (2003) (19)
Chemical and Antigenic Properties of the Cell Wall of Actinomyces viscosus (Strain T6) (1972) (19)
STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. (2013) (18)
Novel and potent 17β-hydroxy steroid dehydrogenase type 1 inhibitors (2005) (17)
A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer. (2008) (16)
The nature of inhibition of steroid sulphatase activity by tibolone and its metabolites (2005) (16)
Characteristics of cystic breast disease with special regard to breast cancer development. (2001) (15)
Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: x-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene. (1999) (15)
Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: Potential therapeutic agents in breast cancer (1994) (14)
STX 140 Is Efficacious In vitro and In vivo inTaxane-Resistant Breast Carcinoma Cells (2008) (13)
Measurement of estrone sulfate in postmenopausal women: comparison of direct RIA and GC-MS/MS methods for monitoring response to endocrine therapy in women with breast cancer. (2007) (13)
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives. (2007) (13)
In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer (2014) (12)
The origin of oestrone sulphate in normal and malignant breast tissues in postmenopausal women. (1992) (12)
STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. (2009) (12)
Effects of mutations and glycosylations on STS activity: A site-directed mutagenesis study (2008) (12)
The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. (2015) (11)
Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy. (2008) (11)
Development of an Oral Formulation for Oestrone 3-O-Sulphamate, a Potent Sulphatase Inhibitor (1996) (11)
Development of a sensitive high-performance liquid chromatography method for the detection of 667 COUMATE in vivo (2003) (10)
The regulation of oestrone sulphate formation in breast cancer cells (1999) (10)
Pharmacokinetics of oestrone-3-O-sulphamate (1996) (10)
Steroid sulfatase inhibitors for the tropical treatment of skin disorders (2008) (10)
A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. (2008) (9)
Inhibition of Steroid Sulfatase Activity in Endometriotic Implants by STX64 (667Coumate): A Potential New Therapy (2008) (9)
Influence of hormonal status of patients with cystic disease on the composition of cyst fluid and breast cancer risk. (2000) (8)
Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity. (2007) (7)
Biochemical control of breast aromatase (2004) (7)
Oestrone sulphatase activity in normal and malignant breast tissues: relationship with tumour location. (1995) (7)
A novel 18 beta-glycyrrhetinic acid analogue as a potent and selective inhibitor of 11 beta-hydroxysteroid dehydrogenase 2. (2004) (6)
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. (2011) (6)
Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases. (2004) (6)
The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer (2008) (6)
Lack of aromatisation of the 3-keto-4-ene metabolite of tibolone to an estrogenic derivative (2006) (6)
Novel, potent inhibitors of 17 beta-hydroxy steroid dehydrogenase type 1 (2006) (5)
X-ray crystal structure and mechanism of action of oestrone 3-O-sulphamate, a synthetic active site-directed inhibitor of oestrone sulphatase (1996) (5)
Tibolone and its delta-4, 7α-methyl norethisterone metabolite are reversible inhibitors of human aromatase (2007) (5)
Inhibition of estrone-dependent tumor growth in vivo by the 17 beta-HSD1 inhibitor, 2-ethyl-16 beta-m-pyridylmethylamidomethyl-estrone (2-EtE1-F). (2006) (5)
A Novel 18β‐Glycyrrhetinic Acid Analogue as a Potent and Selective Inhibitor of 11β‐Hydroxysteroid Dehydrogenase 2. (2004) (4)
First phase I trial of a steroid sulfatase inhibitor in breast cancer. (2004) (3)
Pharmacology of inhibition of estrogen-metabolizing enzymes (1999) (3)
In vivo and in vitro properties of STX 2484 : a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer (2014) (2)
Gross cystic breast disease: overview and directions for future research (1994) (2)
A chimeric microtubule disruptor with efficacy on a taxane resistant cell line (2010) (2)
Use of compound in the manufacture of a pharmaceutical for inhibiting steroid sulphatase and steroid dehydrogenase activity (2001) (1)
2‐Alkylsulfanyl Estrogen Derivatives: Synthesis of a Novel Class of Multi‐Targeted Antitumor Agents. (2004) (1)
Peptide inhibition of cytokine-stimulated aromatase activity in breast tissue fibroblasts (2001) (1)
Regulation of Aromatase in Normal and Malignant Breast Tissues: The Role of the Immune System (2001) (1)
A-ring analogues of oestrone 3-O-sulphamate as potent steroid sulphatase inhibitors and potential anti-cancer agents (2002) (1)
Neutral endopeptidase activity in breast cysts. (1996) (1)
Novel Dual aromatase-steroid sulfatase inhibitors (2006) (1)
Sulphamoylated derivatives of 2-methoxyestradiol induce apoptosis in breast, ovarian and prostate cancer cell lines through mitotic arrest via the intrinsic apoptotic pathway (2006) (1)
Steroid 3-O-sulfamate derivatives as inhibitors of östronsulfatase (1998) (0)
163 POSTER The steroid sulfatase inhibitor BN83495 inhibits E1S-stimulated growth of DMBA-induced mammary tumour in rat (2008) (0)
D-ring modified steroids as potent oestrone sulphatase inhibitors (2002) (0)
Nonsteroidal polycykliskring sulfamate derivatives, their preparation and their use as östronsulfatase (1997) (0)
Polycyclic sulphamate inhibitors of oestrone sulphatase (1997) (0)
Inhibition of growth of tumors derived from MCF-7 cells and MCF-7 cells overexpressing steroid sulfatase by STX64 and STX213 (2006) (0)
Using Sulphamatederivaten as STEROID sulfatase INFLAMMATORY COMPOUNDS (1992) (0)
The use of sulfamate derivatives as steroid sulfatase inhibitors (1992) (0)
Coumarin sulphamates as potent non-steroidal oestrone sulphatase inhibitors (1999) (0)
Composes comportant un groupe sulfamate (1997) (0)
Use of a sulfamatesterholdig sterolic compound for the manufacture of a medicament for the control of estrogen production (1992) (0)
Abstract 727: Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a diaryl template (2010) (0)
Using sulfamate derivatives as inhibitors of steroid sulphatase. (1992) (0)
Estrogen-17-sulfamates as steroid sulfatase inhibitors. (2001) (0)
Inhibition of prostate xenograft growth by two novel orally bioavailable microtubule disruptors (2006) (0)
Prevention of auto-immune disease (2002) (0)
pharmaceutical compositions containing steroid structures and their use. (2001) (0)
Estrogen Transforming Enzymes (1999) (0)
Abstract 4413: STX140 is an orally bioavailable microtubule targeting agent with no associated peripheral neuropathy and potent anti-metastasis efficacy in vivo (2010) (0)
508 POSTER Develooment and evaluation of dual aromatase and sulfatase inhibitors with therapeutic potential (2006) (0)
Derivatives of strogens as inhibitors of steroid sulfatase. (2004) (0)
Compounds comprising a sulphamate group. (1997) (0)
1XQ0: Structure of human carbonic anhydrase II with 4-[(3-bromo-4-O-sulfamoylbenzyl)(4-cyanophenyl)amino]-4H-[1,2,4]-triazole (2005) (0)
The effects of an aromatase inhibitor (anastrozole) or sulfatase inhibitor (STX64) on androgen concentrations in postmenopausal women with breast cancer. (2006) (0)
The steroid sulfatase inhibitor BN83945 inhibits the E1S stimulated growth of DMBA induced mammary tumors in rat (2008) (0)
121 Synthesis, anti-proliferative and anti-angiogenic effects of sulfamoylated 2-methoxyestradiol analogues (2004) (0)
Derivatives of 3-o-steroid sulfamate as estrone sulfatase inhibitors. (1998) (0)
Endocrine and clinical responses to steroid sulfatase inhibition: Results from the first phase I trial in women with breast cancer. (2006) (0)
Steroid sulfate transporters : Novel targets for breast cancer treatment. (2006) (0)
Discovery and development of sulfatase inhibitors via academia, biotech & mid-size pharma (2007) (0)
In vivo inhibition of angiogenesis and tumor growth by sulfamoylated derivatives of 2-methoxyestradiol, STX 140 and STX 641 (2006) (0)
Steroid sulfamates: Potent inducers of apoptosis. (2000) (0)
The steroid sulfatase inhibitor BN-83495 inhibits the growth of DMBA induced mammary tumors in rats alone or in combination with estradiol receptor blockers (2011) (0)
Effect of aromatase inhibitor or tamoxifen therapy on steroid sulfatase activity and DHEA-DHEAS concentrations in postmenopausal women with breast cancer (2008) (0)
Phase I trial of a steroid sulfatase inhibitor, 667 Cournate, in breast cancer (2004) (0)
2-Substituted estradiol bis-sulfamates: SAR, interaction with CAII and anti-tumor activity (2005) (0)
Inhibition of Ovarian Cancer Cell Growth by 2-Methoxyoestradiol-6-oxime (2002) (0)
Prostate and ovarian cancer cell responses to treatment with 2-substituted oestrogen sulphamates in vitro (2003) (0)
2-methoxyestradiol sulphamatas induce G2-M arrest and apoptosis in ER-VE MDA-MB-231 breast cancer cells (2002) (0)
446 Optimisation of tetrahydroisoquinoline based microtubule disruptors as anti-cancer agents (2010) (0)
Inhibition of steroid sulfatase by 667 COUMATE (STX64): a new treatment paradigm for breast cancer (2005) (0)
Abstract 756: Optimization of tetrahydroisoquinoline-based microtubule disruptors as anticancer agents (2010) (0)
Development and evaluation of dual aromatase and sulfatase inhibitors with therapeutic potential (2006) (0)
Advances in Brief In Vivo Inhibition of Estrone Sulfatase Activity and Growth of Nitrosomethylurea-induced Mammary Tumors by 667 COUMATE 1 (2000) (0)
The method steroidisulfataasi containing inhibitors for the preparation of drugs (2000) (0)
Abstract #5562: Discovery of tetrahydroisoquinoline based microtubule disrupting agents with in vivo anti-angiogenic activity (2009) (0)
Steroid sulphatase inhibition: From concept to clinical trial (2005) (0)
Abstract 1558: STX140 but not paclitaxel inhibits mammary tumor initiation, progression and metastasis in C3(1)/SV40 T/t-antigen transgenic mice (2010) (0)
Immunochemical specificity of placental NADPH cytochrome c (P-450) reductase in neoplastic and non-neoplastic human tissue (1992) (0)
Estrogen-Sulphamate-17 for the inhibition of steroid sulfatase (2001) (0)
Steroidal compounds as inhibitors steroid sulphatase (2007) (0)
Pharmaceutical mixtures containing Sulphamatderivate as steroidsulfatasehemmende compounds (1992) (0)
STX2171, a 17 beta-Hydroxysteroid Dehydrogenase Type 3 (17 beta-HSD3) Inhibitor, Is Efficacious In Vivo in a Novel Hormone-Dependent Prostate Cancer Model. (2010) (0)
Irish Association for Cancer Research (1995) (0)
Oestrone-3-methylphosphonothioate (E1MPT) is a potent inhibitor of oestrone sulphatase activity in MCF-7 human breast cancer cells (1992) (0)
Process for the preparation of pharmaceutical compositions containing the steroid sulfatase inhibitor of the compositions (2000) (0)
Reciprocal regulation of oestrone sulphate formation and hydrolysis in breast cancer cells by breast cyst fluid (1997) (0)
Tricyclic coumarin sulphamates as potential therapeutic agents for treating breast cancer. (2000) (0)
2-Methoxyestradiol-3,17-O,O-bis-sulfamate binds to the colchicine site of tubulin and down-regulates survivin, inhibits the anti-apoptotic protein Bcl-2 and down-regulates the pro-angiogenic transcription factor HIF-1 alpha (2006) (0)
2-Substituted estra-1,3,5(10)-trienes as anti-cancer agents: D-ring SAR and in vivo activity (2007) (0)
Use of a sulfatase and aromatase inhibitor in combination for the treatment of human breast cancer. (2006) (0)
Oestrogenderivate as steroid sulphatase inhibitors (2004) (0)
2-Substituted estradiol sulfamates: D-ring SAR and anti-tumor activity (2006) (0)
1TTM: Human carbonic anhydrase II complexed with 667-coumate (2004) (0)
STX2171, a 17b-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model (2013) (0)
226 Sulphamoylated 2-substituted oestrogens induce apoptosis through G2-M checkpoint arrest (2004) (0)
The effects of paclitaxel and STX140 on early-and late-stage breast cancer in tte clinically relevant C3(1)/SV40 mouse model (2011) (0)

This paper list is powered by the following services:

Other Resources About Michael J. Reed

en.wikipedia.org

What Schools Are Affiliated With Michael J. Reed?

Michael J. Reed is affiliated with the following schools:

Michael J. Reed's Academic­Influence.com Rankings

Michael J. Reed's Degrees

Why Is Michael J. Reed Influential?

Michael J. Reed's Published Works

Published Works

Other Resources About Michael J. Reed

What Schools Are Affiliated With Michael J. Reed?

Michael J. Reed's AcademicInfluence.com Rankings